WHO ICTRP trial
Ruxolitinib in the treatment of transplantation related autoimmune cytopenia
ChiCTR2300077788 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300077788 |
|---|---|
| Public title | Ruxolitinib in the treatment of transplantation related autoimmune cytopenia |
| Scientific title | Ruxolitinib in the treatment of transplantation related autoimmune cytopenia |
| Primary sponsor | Medical Center of Hematology, Xinqiao Hospital of Army Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | transplantation related autoimmune cytopenia |
| Interventions | Ruxolitinib group:Weight <25kg, 2.5mg, weight = 25kg, 5mg, take orally once or twice a day; According to the condition and tolerance, the maximum dose can be increased to 10mg/time, twice a day;Prednisone group:1-2mg/kg/d to start treatment… |
| Registration date | Nov 20, 2023 |
| Target size | Ruxolitinib group:30;Prednisone group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: